Clinical Trial Update: Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer [Phase 4]

View source ↗

Summary

Phase 4 trial comparing albumin-bound paclitaxel plus carboplatin to epirubicin and docetaxel for triple-negative breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Albumin-bound paclitaxel (nab-paclitaxel)
• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)
• Epirubicin (epirubicin)

Snippet

Sponsor: Shengjing Hospital | Conditions: Breast Cancer | Phase 4 | Status: RECRUITING